doi:10.1111/obr.13537 Rojas-Gonzalez A, Figueroa-Hernandez CY, Gonzalez-Rios O, et al
J.SmithM
Coverage policies vary widely: a KFF 2025 employer survey found 43% of firms with 5,000+ workers now cover GLP-1 weight-loss drugs (up from 28% in 2024) ( [6] ), yet many patient advocacy reports and journalists note patients cutting doses or resorting to unapproved sources due to cost ( [4] ) ( [7] )
Both dosage regimens were effective, and the effects did not differ significantly between the two dosages
3.3.2 Dulaglutide DUL is a long-acting GLP-1R agonist which can promote insulin secretion, inhibit gastric emptying, and reduce appetite
We found that in hepatoma HepG2 cells, cystine (oxidized form of cysteine) activated mTORC1 and suppressed the ISR